This paper appears in the following: News Double Paper Alert—A Function for BACE, a Basis for Amyloid 22 Sep 2006 Eibsee: Soft Cocktail—In Search of Gentle Knocks To BACE and γ 5 Jan 2009 Barcelona: Out of Left Field—Hit to The Eye Kills BACE Inhibitor 30 Mar 2011 Dual Secretase Approach Shows Promise in AD Mice 8 Jan 2010 Off BACE: Lack of Secretase Causes Seizures in Knockout Mice 5 Jul 2010 DC: Aβ Clearance—Roles for MBP, Transcription Factors? 26 Nov 2008 Glial γ-Secretase Inhibits Myelination in New CNS Co-culture System 13 Feb 2009 BACE Knockouts Show More Synaptic Troubles 5 Sep 2008 San Diego: Merck Reports BACE Inhibition in Primates 11 Dec 2007 Keystone Drug News: CoMentis BACE Inhibitor Debuts 5 Apr 2008 Call in BACE1 Inhibitors for Nerve Repair Duty? 30 Apr 2011 Neuregulin/ErbB4 Mutant Mice Have Myelin, Synaptic Deficits 3 May 2007 Shape-shifting Prions: Infectious Recombinant and Myelin-Minding Normal 3 Feb 2010 Enabling Technologies for Alzheimer Disease Research: Seventh Bar Harbor Workshop, 2007, Part 1 22 Dec 2007 Paracrine Signal From BACE1-Clipped Neuregulin Rescues Myelin 13 May 2013 Paper Alert: BACE1 Required for Muscle Spindle, Motor Control 3 Jul 2013 De Strooper, Goedert, Hardy, Haass Share 2018 Brain Prize 8 Mar 2018 In Conditional BACE1 Knockouts, Hippocampal Axons Compromised 21 Sep 2018
University of Pennsylvania
The studies by Meyer-Luehman et al. extend insights into the in vivo formation of amyloid deposits by amyloid "seeds" that may be hetero- and/or homo-amyloidogenic inducers of amyloid fibrillization. This is significant because these types of studies will lead to the clarification of the perplexing conundrum of why there is a frequent co-occurrence of multiple different types of amyloids in neurodegenerative disorders characterized by brain amyloidosis. Indeed, double and triple neurodegenerative brain amyloidoses appear to far exceed in incidence and prevalence any neurodegenerative brain amyloidosis linked to a single amyloidogenic protein or peptide, and this enigma demands clarification if we are to develop more effective therapies for these disorders.
For example, with respect to Aβ deposits, these may occur by themselves as pathological signatures of single brain amyloidoses, such as cerebral amyloid angiopathy (CAA), which most commonly manifests clinically as stroke. This notwithstanding, CAA is more commonly an incidental finding in neurologically normal individuals, suggesting that Aβ deposits may not be sufficient in and of themselves to cause a neurodegenerative dementing disease. In contrast, neurodegenerative dementia linked to Aβ amyloidosis is commonly a double or triple brain amyloidosis with coexistent tau amyloid (in the form of neurofibrillary tangles, or NFTs), and this dementia is, of course, known as Alzheimer disease (AD).
However, most familial and sporadic cases of AD are actually triple brain amyloidoses since α-synuclein amyloid also is deposited in Lewy bodies (LBs) together with NFTs and senile plaques, and this disorder is known as the LB variant of AD (LBVAD). Notably, LBVAD is the most common subtype of AD. Recent studies from the Lee/Trojanowski group have begun to dissect out mechanisms whereby α-synuclein and tau can cross-seed the fibrillization of each other to form amyloid fibrils, and further research on this may help clarify the common co-occurrence of LBs and tangles in the same patient (1).
Additionally, further studies are needed to understand how tau and Aβ might cross-fibrillize or promote the fibrillization of each other. Much earlier studies by our group demonstrated potential avenues to explore these issues further—using model systems that antedated the development of transgenic mouse models of brain amyloidoses—by injecting purified PHFtau into rat brains, which induced deposits of Aβ associated with the PHFtau injection sites (2,3). However, transgenic mouse models of brain amyloidoses resulting from the overexpression or regulatable expression of mutant or wild-type tau and α-synuclein or the Aβ precursor protein are much more powerful model systems in which to explore these questions further. This is demonstrated very elegantly in the studies by Meyer-Luehman et al. Further dissection of the cross-seeding by hetero- and/or homo-amyloidogenic inducers of amyloid fibrillization could extend these elegant studies by immunodepletion of AD and LBVAD extracts to remove not only Aβ, but also tau amyloid and α-synuclein amyloid to understand the differential contributions of each of these three amyloidogenic proteins in the induction of Aβ.
Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003 Apr 25;300(5619):636-40. PubMed.
Shin RW, Bramblett GT, Lee VM, Trojanowski JQ. Alzheimer disease A68 proteins injected into rat brain induce codeposits of beta-amyloid, ubiquitin, and alpha 1-antichymotrypsin. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6825-8. PubMed.
Shin RW, Lee VM, Trojanowski JQ. Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro. J Neurosci. 1994 Nov;14(11 Pt 2):7221-33. PubMed.View all comments by John Trojanowski
National Institute on Aging
BACE1 is the principal β-secretase for generation of amyloid-β peptides. Since the identification of BACE1, several lines of BACE1 knockout mice have been made, which are viable and show no major behavioral and pathological abnormalities, suggesting that BACE1 is a safe therapeutic target for Alzheimer disease (AD). Notably, some BACE1 KO mice show premature lethality and subtle alterations in emotional response and locomotor activities. BACE1 KO neurons also display subtle changes in synaptic plasticity and sodium conductance. These deficits are not noted in all the reported mice, but similar discrepancies in behavioral phenotyping have been noticed in mice derived from different strain backgrounds and gene targeting vectors.
Willem and colleagues are the first to show a convincing neuropathological abnormality in BACE1 KO mice. An observation that the highest expression of BACE1 protein correlates with the onset of peripheral nerve myelination promotes them to examine the progression of myelination in the sciatic nerve of BACE1 KO mice. They find that axons of BACE1 KO mice are hypomyelinated from early postnatal stages to adulthood. Interestingly, mice deficient in cell-cell signaling protein type III neuregulin 1 (NRG1-β3) and its receptor, ErbB, display a very similar hypomyelination in peripheral axons, indicating a cross-talk between BACE1 and the NRG1-β3/ErbB signaling pathway. In line with this notion, membrane-bound NRG1 full-length protein accumulated in BACE1 KO mice and exogenous expression of BACE1 increased the release of the NRG1 ectodomain in culture, suggesting that NRG1-β is a novel substrate for BACE1. The cleavage by BACE1, or in combination with TACE, may result in the release of the EGF-like domain of NRG-β from neurons. This domain interacts with the receptor tyrosine kinase ErbB at the surface of Schwann cells, promoting the myelination process. It appears that BACE1 cleaves NRG1-β at the stalk region, but the precise cleavage site has not been revealed.
There are two major questions to be addressed in the future research. The first question is whether the lack of BACE1-mediated cleavage of NRG-β is solely responsible for the hypomyelination in BACE1 KO mice. Willem and colleagues’ findings do not completely rule out the involvement of other BACE1 substrates. For example, it will be interesting to examine whether the myelination is altered in APP KO mice, which display decreased locomotor activity and forelimb grip strength. The second question is whether BACE1 is involved in other functions of NRG1 family signaling molecules. NRG1 plays many essential roles in the CNS, heart and other peripheral tissues. It is important to revisit BACE1 KO mice to examine potential pathology in these systems.
In summary, Willem and colleagues reveal a novel function of BACE1 in myelination. The findings raise some concern about the safety of inhibiting BACE1 as a treatment for AD. Nevertheless, the generally healthy BACE1 KO mice still make BACE1 the best therapeutic target for the inhibition of Aβ production in AD.View all comments by Huaibin Cai
It’s a Wrap; Axonal Myelination Is Regulated by the Alzheimer Disease Target, BACE
A fundamental developmental process has once again crossed paths with a major player in the pathogenesis of Alzheimer disease. Shortly after its discovery, BACE, via its interaction with neuregulin-1, has been implicated in the molecular neurobiology of central and peripheral axon myelination. Data from several labs have shown that specific members of the neuregulin-1 (NRG1) family of trophic factors are critical to Schwann cell differentiation, proliferation, survival, and now to the process of myelination itself. Whether axons are myelinated singly (and the number of myelin wraps required) or left unmyelinated and ensheathed in bundles, is governed by expression of the type III isoform of neuregulin-1 (Michailov et al., 2004; Taveggia et al., 2005; Chen et al., 2006; Ogata et al., 2004): It is the expression level of NRG1 that communicates axon caliber to the Schwann cell.
Neuregulin-1 isoforms are ligands for heterodimeric combinations of ErbB receptor tyrosine kinases, specifically ErbB2, B3 and B4 (the EGF receptor is known as ErbB1). After binding to their cognate receptors, these ligands induce tyrosine phosphorylation and subsequent downstream activation of the PI3K (phosphatidyl inositol-3 kinase) pathway (Maurel and Salzer, 2000). The importance of neuregulin-1 cannot be overemphasized: pan-NRG1 as well as ErbB2, ErbB3, and ErbB4 KO mice are each embryonic lethals, and neuregulin-1 gene products in the CNS have been implicated in numerous other processes including neurotransmitter receptor regulation (see review by Falls, 2003).
Akt is the signaling node downstream of neuregulin and PI3K that is most implicated in survival and the specialization of Schwann cells and oligodendrocytes to form myelin (Flores et al., 2000; Li et al., 2001; Taveggia et al., 2005). Akt is already familiar to those studying neurodegeneration, motor neuron disease, and schizophrenia (Emamian et al., 2004; Humbert et al., 2002; Kaspar et al., 2003; Magrane et al., 2004). In Schwann cells, Akt transduces the neuregulin signal to inactivate the proapoptotic proteins Bad (Li et al., 2001) and GSK3β (Ogata et al., 2004), as well as to increase the expression of proteins that specify myelin differentiation: MAG (Ogata et al., 2004); P0; PMP22; and MBP (Chen et al., 2006). The transcription factors, Oct-6 and Krox-20 fill in the signal cascade (Taveggia et al., 2005).
What’s new in two recent papers is that type III neuregulin-1 has become the newest substrate of BACE-1, indicating this enzyme has an essential role to play in the decision to myelinate axons, and by how much. The studies by Hu et al. (2006) and Willem et al. (2006) have implicated BACE-1, the β-secretase enzyme for the amyloid precursor protein, as being a critical regulator of the levels of cleaved type III neuregulin-1. Hu et al. decided to examine myelination in BACE-1 deficient mice because BACE is transported into axons, along with APP, by a kinesin-1-dependent pathway. Willem et al. on the other hand noted that BACE-1 expression is highest in the developmental period corresponding to peripheral myelination. Both papers show that in the absence of BACE-1, myelination is reduced to the same degree as is seen in neuregulin hypomorphs (having only one copy of the NRG1 gene) or in conditional knockdowns of ErbB2. Measurement of the g-ratio (interior/exterior fiber diameter) shows a significant reduction in the number of myelin wraps associated with both central and peripheral axons when the BACE-1 gene has been inactivated. In the Hu et al. study, the decrease in myelination paralleled a reduction in expression of compact myelin proteins such as myelin basic protein (MBP) and the proteolipid protein (PLP). Willem et al. show through the added generation of BACE-1/2 compound mutants and BACE-2 mutant mice that BACE-1 activity alone is responsible for the hypomyelination phenotype. It is interesting that BACE-deficient mice also show abnormal bundling of small-diameter, unmyelinated axons (Willem et al.), in agreement with Taveggia et al., who use co-cultures of NRG1-/- neurites with Schwann cells to prove that NRG1 signaling is required for this critical function, too. Thus, normal ensheathment is not a default in the absence of NRG1 or BACE.
In both studies, the absence of BACE-1 leads to the accumulation of the inactive, full-length type III neuregulin-1 precursor and a corresponding decrease in the cleavage product or active ligand in brain. Presumably, BACE-1 cleaves the transmembrane precursor to release the soluble extracellular domain from the axons. Willem et al. produced a fusion between type III neuregulin-1 and secreted alkaline phosphatase to show that co-transfection with BACE-1 led to a direct increase in cleavage and release of the extracellular fragment. A likely direct interaction between BACE-1 and NRG1 was concluded. The ligand is then free to interact with and activate ErbB receptor tyrosine kinases on adjacent myelinating cells. How this diffusion takes place is presently unclear.
As expected from the loss of NRG1 cleavage in BACE-1-null mice, signaling in the PI3K/Akt pathway is reduced as revealed by the reduction in activated pAkt levels and drops in MBP and PLP in brain (Hu et al.). To prove that BACE-1-/- neurons cannot activate PI3K/Akt signaling in Schwann cells in a functional way might require some added work. This could be addressed, for instance, by showing that an axotomized nerve graft from a normal mouse can rescue myelination of a recovering host BACE-null axon (i.e., after transplantation into the transected defect of a peripheral nerve belonging to a recipient BACE-1-/- mouse) if prior gene transfer with myrAkt is attempted.
It should be emphasized that both authors found heterozygote BACE-1 mice to be phenotypically normal. Moreover, BACE-1 levels drop considerably in the adult state. These alone might suggest that partial inhibition of BACE-1, as advocated for AD therapy, would have no chance for adverse effects. Unfortunately, such mice still produce substantial amounts of β amyloid (Cai et al., 2001; Luo et al., 2001) and do not correct cognitive defects when crossed with APP/PS-1 transgenic AD mice (Laird et al., 2005). Thus, it will still be important to know the full impact of BACE-1 inhibition in the adult animal. A conditional KO model may be one approach to this question. However, there already exist cautionary signs. For instance, it is already known that BACE-1-deficient mice have a number of undesirable effects relating to impaired spatial reference memory and synaptic function (LTD-reversal) (Laird et al., 2005) as well as reduced pain threshold (Hu et al., 2006). BACE inhibition also has the theoretical effect of mitigating the protective back-signaling role of the NRG1-intracellular domain (Bao et al., 2003). Neuregulins may also have beneficial effects on APP metabolism and protection from Aβ (Rosen et al., 2003; Di Segni et al., 2005) that could be susceptible to BACE inhibition. Theoretically, remyelination could be impaired after certain central and peripheral injuries in BACE-1-inhibited patients. Ironically, loss of Notch signaling from inhibition of γ-secretase activity has somewhat dampened the enthusiasm of that approach to reduce Aβ production (Haass, 2004). With every “wrap” there seems to appear an interesting twist, which solves yet another puzzle but never the most important one—how do we treat Alzheimer disease?
Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA. Axonal neuregulin-1 regulates myelin sheath thickness. Science. 2004 Apr 30;304(5671):700-3. PubMed.
Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, Xu X, Esper RM, Loeb JA, Shrager P, Chao MV, Falls DL, Role L, Salzer JL. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron. 2005 Sep 1;47(5):681-94. PubMed.
Chen S, Velardez MO, Warot X, Yu ZX, Miller SJ, Cros D, Corfas G. Neuregulin 1-erbB signaling is necessary for normal myelination and sensory function. J Neurosci. 2006 Mar 22;26(12):3079-86. PubMed.
Ogata T, Iijima S, Hoshikawa S, Miura T, Yamamoto S, Oda H, Nakamura K, Tanaka S. Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J Neurosci. 2004 Jul 28;24(30):6724-32. PubMed.
Maurel P, Salzer JL. Axonal regulation of Schwann cell proliferation and survival and the initial events of myelination requires PI 3-kinase activity. J Neurosci. 2000 Jun 15;20(12):4635-45. PubMed.
Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003 Mar 10;284(1):14-30. PubMed.
Flores AI, Mallon BS, Matsui T, Ogawa W, Rosenzweig A, Okamoto T, Macklin WB. Akt-mediated survival of oligodendrocytes induced by neuregulins. J Neurosci. 2000 Oct 15;20(20):7622-30. PubMed.
Li Y, Tennekoon GI, Birnbaum M, Marchionni MA, Rutkowski JL. Neuregulin signaling through a PI3K/Akt/Bad pathway in Schwann cell survival. Mol Cell Neurosci. 2001 Apr;17(4):761-7. PubMed.
Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004 Feb;36(2):131-7. PubMed.
Humbert S, Bryson EA, Cordelières FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell. 2002 Jun;2(6):831-7. PubMed.
Kaspar BK, Lladó J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003 Aug 8;301(5634):839-42. PubMed.
Magrané J, Smith RC, Walsh K, Querfurth HW. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci. 2004 Feb 18;24(7):1700-6. PubMed.
Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006 Dec;9(12):1520-5. Epub 2006 Nov 12 PubMed.
Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, Destrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006 Oct 27;314(5799):664-6. PubMed.
Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001 Mar;4(3):233-4. PubMed.
Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001 Mar;4(3):231-2. PubMed.
Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005 Dec 14;25(50):11693-709. PubMed.
Bao J, Wolpowitz D, Role LW, Talmage DA. Back signaling by the Nrg-1 intracellular domain. J Cell Biol. 2003 Jun 23;161(6):1133-41. PubMed.
Rosen KM, Ford BD, Querfurth HW. Downregulation and increased turnover of beta-amyloid precursor protein in skeletal muscle cultures by neuregulin-1. Exp Neurol. 2003 Jun;181(2):170-80. PubMed.
Di Segni A, Shaharabani E, Stein R, Pinkas-Kramarski R. Neuregulins rescue PC12-ErbB-4 cells from cell death induced by beta-amyloid peptide: involvement of PI3K and PKC. J Mol Neurosci. 2005;26(1):57-69. PubMed.
Haass C. Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J. 2004 Feb 11;23(3):483-8. PubMed.View all comments by Henry Querfurth
Make a Comment
To make a comment you must login or register.